A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of KRN23 in Adult Patients with X-linked Hypophosphatemia (XLH)¿
Clinical Trial Grant
Administered By
School of Medicine
Awarded By
Ultragenyx Pharmaceutical
Start Date
September 15, 2015
End Date
May 31, 2019
Administered By
School of Medicine
Awarded By
Ultragenyx Pharmaceutical
Start Date
September 15, 2015
End Date
May 31, 2019